Friday 12th May 2017
Anticentromere antibodies associated with better outcomes
Organ involvement occurs later in people with diffuse scleroderma and anticentromere antibodies (ACAs).
Friday 12th May 2017
Organ involvement occurs later in people with diffuse scleroderma and anticentromere antibodies (ACAs).
Thursday 26th May 2016
Cytori Therapeutics Inc. announces that its US FDA-approved phase III STAR trial has enrolled its 80th patient (100% of target enrolment). All 80 patients enrolled thus far in both trial arms have been successfully treated without complications. Full trial data are expected to be available in mid-2017.
Monday 23rd May 2016
On Tuesday 26th through to the 28th of April, The British Society for Rheumatology held their annual conference, with this year’s venue being in Glasgow.
Friday 13th May 2016
Wednesday 11th May 2016
Friday 6th May 2016
Cumberland Pharmaceuticals, Inc., recently announced the addition to its drug pipeline of Vasculan (ifetroban), an oral capsule that soon will enter clinical testing as a treatment of systemic sclerosis (SSc), or scleroderma.